Grade 3 and 4 toxicities and adverse events according to treatment arm
| . | QT + V (%), n = 129 . | TD (%), n = 127 . | VTD (%), n = 130 . |
|---|---|---|---|
| Neutropenia | 29 (22) | 18 (14) | 13 (10) |
| Thrombocytopenia | 8 (6) | 6 (5) | 10 (8) |
| DVT/PE | 5 (4) | 6 (5) | 15 (12) |
| Infection | 20 (15) | 21 (16) | 27 (21) |
| Gastrointestinal | 11 (8) | 3 (25) | 11 (8) |
| Peripheral neuropathy | |||
| Grade 3 | 9 (7) | 6 (5) | 15 (12) |
| Grade 4 | 2 (2) | 0 | 2 (2) |
| Discontinuations during induction | |||
| Toxicity | 4 (3) | 4 (3) | 9 (7) |
| Disease progression | 15 (12) | 29 (23) | 9 (7) |
| Death | 4 (3) | 3 (2) | 3 (2) |
| Consent withdrawal | 0 | 2 (2) | 1 (1) |
| . | QT + V (%), n = 129 . | TD (%), n = 127 . | VTD (%), n = 130 . |
|---|---|---|---|
| Neutropenia | 29 (22) | 18 (14) | 13 (10) |
| Thrombocytopenia | 8 (6) | 6 (5) | 10 (8) |
| DVT/PE | 5 (4) | 6 (5) | 15 (12) |
| Infection | 20 (15) | 21 (16) | 27 (21) |
| Gastrointestinal | 11 (8) | 3 (25) | 11 (8) |
| Peripheral neuropathy | |||
| Grade 3 | 9 (7) | 6 (5) | 15 (12) |
| Grade 4 | 2 (2) | 0 | 2 (2) |
| Discontinuations during induction | |||
| Toxicity | 4 (3) | 4 (3) | 9 (7) |
| Disease progression | 15 (12) | 29 (23) | 9 (7) |
| Death | 4 (3) | 3 (2) | 3 (2) |
| Consent withdrawal | 0 | 2 (2) | 1 (1) |
QT + V indicates chemotherapy + bortezomib; TD, thalidomide/dexamethasone; VTD, bortezomib/thalidomide/dexamethasone; DVT, deep vein thrombosis; and PE, pulmonary embolism.